To investigate whether children who consumed infant formula supplemented with long-chain polyunsaturated fatty acids (LCPUFAs) had a more favourable cardiovascular profile than children who consumed formula without these fatty acids, we used the Wheezing Illnesses Study Leidsche Rijn, a birth cohort that included 2,468 newborns between 2001 and 2014. Data on infant feeding were obtained by questionnaires. At age 5, blood pressure, carotid intima-media thickness (CIMT), and carotid distension were measured. We used multivariable linear regression analysis to compare levels of cardiovascular markers in formula-fed children born before and after the LCPUFA supplementation. To account for secular trends, we compared levels of cardiovascular markers in a control group of breastfed children from the same cohort born before and after the supplementation. Formula-fed children born after the LCPUFA supplementation (n = 48) .6]) and had a higher CIMT (18.6 μm, 95% CI [3.7, 33.5]) than formula-fed children born before the supplementation (n = 163). In the control group, children born after the LCPUFA supplementation (n = 98) had no different systolic-or diastolic-blood pressure, or CIMT, and a higher carotid distension than children born before the supplementation (n = 142).
| INTRODUCTION
Consumption of long-chain polyunsaturated fatty acids (LCPUFAs), especially those found in fatty fish, has a favourable effect on blood pressure and serum markers of cardiovascular disease risk in adults (Balk et al., 2004; Miller, Van, & Alexander, 2014) . Until around 2006 in the Netherlands, infant formulae did not contain these LCPUFAs, and it has therefore been hypothesized that supplementing formulae with LCPUFAs will improve the cardiovascular profile in formula-fed children. The evidence for a beneficial effect on blood pressure in childhood, however, is conflicting (de Jong, Boehm, Kikkert, & Hadders-Algra, 2011; Forsyth et al., 2003) .
In 2006, Dutch nutrition companies have started supplementing retail formulae with LCPUFAs based on evidence of beneficial effects on visual development in infancy (Birch et al., 2005; Hoffman et al., 2003) . We used this formula supplementation as a natural experiment to investigate our hypothesis that children who consumed formula with LCPUFAs had a more favourable cardiovascular profile than children who consumed formula without LCPUFAs. We used data from the Wheezing Illnesses Study Leidsche Rijn (WHISTLER), a prospective birth cohort study that enroled newborns between 2001 and 2014. To take account of secular trends in related exposures during this period, we compared levels of cardiovascular markers in a control group of breastfed children in the same cohort who were born before and after the supplementation.
| Study population
Of the 942 children who visited the outpatient clinic at age 5 years, 822 children had complete data on the type and duration of infant feeding and were eligible to participate (Figure 1 ). Of these 822 children, 232 children (28.2%) received exclusive formula feeding, 163 children received formula without LCPUFAs (blood pressure measurements in 143 children, carotid intima-media thickness [CIMT] in 147 children, and carotid distension in 131 children), 48 children received formula with LCPUFAs (blood pressure measurements in 47 children, CIMT in 46 children, and carotid distension in 39 children), and 21 children were excluded because of uncertainty about LCPUFA supplementation at the date of birth. Another 275 children (33.5%) received exclusive breastfeeding for at least 3 months and were defined as the control group, 142 children were born before formula feedings were supplemented with LCPUFAs (blood pressure measurements in 130 children, CIMT in 126 children, and carotid distension in 115 children), 98 children were born after the supplementation (blood pressure measurements in 96 children, CIMT in 94 children, and carotid distension in 81 children), and 35 children were excluded because of uncertainty about LCPUFA supplementation at the date of birth. The remaining 315 children (38.3%) received both breastfeeding and formula feeding simultaneously and were excluded from this study.
| Collection of data on infant feeding
At baseline when infants were 4 weeks old and in the 11 subsequent months, the type of infant feeding was ascertained via parental questionnaires by asking "Has your child been breastfed this month?" Answering options were "yes, exclusively breastfed," "yes, both breastfed and formula fed," and "no, exclusively formula fed." In case the child received formula feeding, the brand of the infant formula was inquired. All questionnaires were returned by mail, and parents received monthly reminders to return them.
| Definition of infant feeding
Formula feeding was defined as receiving exclusive formula feeding from birth onwards (n = 162) or receiving both breastfeeding and formula feeding in the first week(s), but switching to exclusive formula feeding in the first month after birth (n = 70). In total, 232 children were classified as being formula fed. Breastfeeding was defined as receiving exclusive breastfeeding from birth until at least 3 months of age (n = 275).
| Definition of exposure: Infant formula supplemented with LCPUFAs
The type of infant formula that each child received was identified by extracting the formula brands that were reported in the baseline questionnaire. Nutritionists of the two infant feeding companies that formulas were most often used by our study population (Table 1) provided information on the year and month in which LCPUFAs were added to their formulas. For the six children who received other • LCPUFAs are associated with cardiovascular health in adults, but it is unknown whether the current supplementation of infant formulas with LCPUFAs is also beneficial for cardiovascular health in children.
• Our results show that children who received infant formula with n-3 LCPUFAs had no different blood pressure or carotid distension and had a higher intima- Table S1 . Besides the LCPUFAs supplementation, no other nutrients were added to or removed from the formulae over the duration of the study. In Nutrilon, there were small increases in the amount of proteins (1.4-1.6 g) and carbohydrates (7.5-7.7 g). In Nutrilon and
Friso formula, there were small changes in the amount of vitamins and minerals.
2.6 | Measurement of the outcome variables: Blood pressure, CIMT, and carotid distension during followup visit at 5 years of age Coefficients of variation based on measurements by one observer in 10 subjects at two occasions for distension and CIMT were 7.1% and 4.3%. During ultrasonography, blood pressure was recorded twice in the brachial artery using a semiautomatic oscillometric device with cuff size adjusted to the children (DINAMAP; Criticon, Tampa, FL, USA). 
| Definition of the outcome variables
Outcome variables were defined as mean levels of systolic blood pressure (SBP), diastolic blood pressure (DBP), CIMT, and carotid distension. In each individual child, SBP and DBP were calculated as the mean from the two repeated measurements. Mean CIMT and mean carotid distension were calculated from the maximum of four repeated measurements. Mean carotid distension was adjusted for mean arterial pressure (systolic blood pressure + 2 * (diastolic blood pressure)/3) and for the end-diastolic diameter of the common carotid artery.
| Covariates
Based on differences observed between children born before and after the supplementation of formula with LCPUFAs, we included maternal educational level and maternal smoking during pregnancy as potential confounders in the analyses. We also included body mass index (BMI) at 5 years of age because this factor may lie on the causal pathway in the associations between formula supplemented with LCPUFAS and SBP, DBP, CIMT, and carotid distension. BMI was calculated from measured weight and height (weight in kg/height squared in m) during the 5-year visit at the outpatient clinic. In the analysis of the control group of breastfed children, we also included maternal age at birth as a potential confounder.
| Statistical analysis
Means (SD) and percentages (N) of maternal and child characteristics were described in children born before and after the supplementation of formula with LCPUFAs. Linear regression analysis was used to investigate differences in mean levels of SBP, DBP, CIMT, and carotid distension between children who received formula with LCPUFAs and children who received formula without LCPUFAs (=reference category). In multivariable models, we adjusted for potential confounders. In separate models, we added BMI at 5 years of age.
To take account of secular trends in relevant exposures over the 8-year measurement period, for example, changes in active or passive smoke exposure due to the introduction of a smoking ban in public places in 2008, we also compared cardiovascular markers in a control group of breastfed children who were born before (n = 142) and after (n = 98) supplementation of formula with LCPUFAs. 
| Differences in cardiovascular markers between children born before and after 2006
In formula-fed children born before 2006, the mean SBP was 103.1 mmHg, mean DBP was 53.7 mmHg, mean CIMT was 380.9 μm, and mean carotid distension was 788.5 MPa −1 (Table 3) Formula -LCPUFAs: n = 66 Excl.: n =14 Formula + LCPUFAs: n = 6 FIGURE 2 Number of children who received Nutricia or Friso formula with and without long-chain polyunsaturated fatty acids (LCPUFAs) (24. b Formula-fed children born before and after formula feedings were supplemented with long-chain polyunsaturated fatty acids.
c Control group of breastfed children born before and after formula feedings were supplemented with long-chain polyunsaturated fatty acids.
Maternal educational level was defined as follows: Low level (until lower secondary professional education), intermediate level (higher general secondary education, pre-university education), and high level (higher professional education, university).
d Significantly different from control <2006 (t test p value <.05) Formula-fed children born before and after formula feedings were supplemented with long-chain polyunsaturated fatty acids.
b Control group of breastfed children born before and after formula feedings were supplemented with long-chain polyunsaturated fatty acids. SBP = systolic blood pressure; DBP = diastolic blood pressure; CIMT = carotid intima-media thickness. Note. SBP = systolic blood pressure; DBP = diastolic blood pressure; CIMT = carotid intima-media thickness; CI = confidence interval.
a Formula-fed children born after versus before formula feedings were supplemented with long chain polyunsaturated fatty acids.
b Control group of breastfed children born after versus before formula feedings were supplemented with long-chain polyunsaturated fatty acids.
Carotid distension was adjusted for mean arterial pressure and for the end-diastolic diameter of the common carotid artery c Adjusted for maternal educational level and maternal smoking during pregnancy. 2006. Additional adjustment for BMI at 5 years of age did not alter the associations (data not shown). Associations were similar when we excluded children who switched from (partial) breastfeeding to exclusive formula feeding in the first month (data not shown).
| DISCUSSION
Children who consumed infant formula supplemented with LCPUFAs A strength of our study is the reliable data on exposure because we prospectively assessed the type and duration of infant feeding, as well as the used formula brands, by using monthly questionnaires in the child's first year of life. Another strength is the long period of subject enrolment in WHISTLER, which allowed us to design a study in which time was the only factor that determined whether a child as these children have been exposed to similar secular changes. Nevertheless, unmeasured confounding cannot be completely ruled out, and a causal relationship between infant formula with LCPUFAs and CIMT in childhood cannot be proven with this study. Another limitation of our study is the lack of power to perform subgroup analyses, that is, to assess whether associations differ between boys and girls.
Children who received formula supplemented with LCPUFAs tended to have a lower SBP than children who received formula without LCPUFAs, but the difference was not statistically significant.
No difference in DBP was observed between those who consumed formula with and without LCPUFAs. In the control group, no differences in SBP or DBP were observed between children born before and after the supplementation. In a European multicenter trial, consumption of formula supplemented with LCPUFAs until 4 months of age was associated with a similar decrease in SBP as in our study at 6 years of age, which was accompanied by a 3.6 mmHg lower DBP (Forsyth et al., 2003) . In another study, consumption of formula with LCPUFAs until 2 months of age was not associated with either SBP or DBP at the age of 9 years (de Jong et al., 2011) . Because only a few studies investigated an association between formula supplemented with LCPUFAs and blood pressure in childhood, more studies are needed to reach a final conclusion of the association.
To our knowledge, no previous study has investigated an association between formula supplemented with LCPUFAs and CIMT in childhood. Our observed higher CIMT in children fed supplemented formula seems unexpected, because a higher CIMT in adults indicates atherosclerotic plaque progression (Bots & Grobbee, 2002) . In the paediatric population, CIMT is also regarded as an indicator of vascular health (Urbina et al., 2009) . Statistically significant increases in CIMT of 0.2 , 0.05 , and 0.03 mm were already observed in, respectively, obese (Reinehr, Kiess, de Sousa, Stoffel-Wagner, & Wunsch, 2006) , diabetic (Järvisalo et al., 2002) , and hypercholesterolemic children (Pauciullo et al., 1994) . In a previous study conducted within WHISTLER, with follow-up before LCPUFA supplementation in formula was introduced, we showed that children who received breastfeeding had a higher CIMT at 5 years of age than children who received formula feeding (Evelein et al., 2011) . Breast milk contains LCPUFAS, whereas at that time, infant formulae did not. We discussed that the higher CIMT might reflect a short-term effect of high cholesterol exposure due to a high cholesterol concentration in breast milk. In the current study, cholesterol unlikely explains the observed higher CIMT because its level in formula feeding has not changed throughout the study period.
Besides the LCPUFA supplementation, small changes were made in the amount of proteins and carbohydrates (Nutrilon) and in the amount of some vitamins and minerals (Nutrilon and Friso). We assume that this has not affected our results as these small changes are unlikely to have clinical relevance, and most of these nutrients are irrelevant for the outcomes of our study.
We can only speculate about the implications of a higher CIMT in childhood for future cardiovascular risk. Thickening of the inner walls of the arteries is a slow process that tracks over time (Salonen & Salonen, 1991) . Follow-up measurements in WHISTLER at 8 years of age and beyond will clarify whether children who received formula supplemented with LCPUFAs will continue to have a higher CIMT throughout childhood and will help to understand the implications of these findings for future health. Nevertheless, more studies are needed to investigate an association between formula supplemented with LCPUFAs and CIMT in childhood before firm conclusions can be made.
In accordance with the observed higher CIMT, children fed formula with LCPUFAs tended to have a higher carotid distension than children fed formula without LCPUFAs, but the difference was not statistically significant. In the control group, breastfed children born after the supplementation had a statistically significantly higher carotid distension than those born before the supplementation. If this underlies a secular trend for carotid distension, this may actually mean that carotid distension did not improve in formula-fed children born after 2006, in a similar direction as for CIMT.
pressure and carotid distension and had a higher CIMT than children who consumed infant formula without LCPUFAs. Randomized controlled trials need to study whether the higher CIMT is a consequence of the LCPUFA supplementation or whether changes in unknown risk factors over time have confounded the observed associations.
